Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Imbrium Completes Clinical Trial of Treatment for Interstitial Cystitis/BPS
Details : IMB-115 (sunobinop) is designed to bind to and activate the nociceptin/orphanin-FQ peptide receptor (NOP), being investigated for treatment of overactive bladder syndrome.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 11, 2025
Imbrium Therapeutics Announces Results from Phase 1b Study in OAB Syndrome
Details : IMB-115 (sunobinop) is designed to bind to and activate the nociceptin/orphanin-FQ peptide receptor (NOP), being investigated for treatment of overactive bladder syndrome.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2025
Lead Product(s) : Sunobinop
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Purdue Pharmaceuticals L.P
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 09, 2024
Lead Product(s) : Sunobinop
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Purdue Pharmaceuticals L.P
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sunobinop
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Purdue Pharmaceuticals L.P
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Sunobinop on Craving in Alcohol Use Disorder
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 09, 2024
Lead Product(s) : Sunobinop
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Purdue Pharmaceuticals L.P
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sunobinop
Therapeutic Area : Psychiatry/Psychology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Imbrium Submits IND Application to Evaluate Sunobinop for Alcohol Use Disorder
Details : IMB-115 (sunobinop) is designed to bind to and activate the nociceptin/orphanin-FQ peptide receptor (NOP), being investigated for treatment of moderate to severe alcohol use disorder.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 08, 2024
Lead Product(s) : Sunobinop
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sunobinop
Therapeutic Area : Urology
Study Phase : Phase I
Sponsor : Purdue Pharmaceuticals L.P
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 29, 2024
Lead Product(s) : Sunobinop
Therapeutic Area : Urology
Highest Development Status : Phase I
Sponsor : Purdue Pharmaceuticals L.P
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sunobinop
Therapeutic Area : Urology
Study Phase : Phase I
Sponsor : Purdue Pharmaceuticals L.P
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of V117957 in Overactive Bladder Syndrome
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 06, 2023
Lead Product(s) : Sunobinop
Therapeutic Area : Urology
Highest Development Status : Phase I
Sponsor : Purdue Pharmaceuticals L.P
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IMB-150 (also known as LYT-503) as a potential non-opioid treatment for female patients with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). IMB-150, is a novel formulation of lidocaine, and the clinical development program is called GainMe-IC.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 20, 2022
Lead Product(s) : IMB-150
Therapeutic Area : Urology
Study Phase : Preclinical
Recipient : PureTech Health
Deal Size : $59.5 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Imbrium is responsible for all future development activities and funding for LYT-503/IMB-150, for which an IND filing is planned for early 2022.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 08, 2021
Lead Product(s) : IMB-150
Therapeutic Area : Urology
Highest Development Status : Preclinical
Recipient : PureTech Health
Deal Size : $59.5 million
Deal Type : Licensing Agreement
Imbrium Therapeutics Presents First Data and Describes Novel Mechanism of Action For IMB-115
Details : IMB-115 is a novel, highly potent and selective partial agonist for nociceptin/orphanin-FQ peptide (NOP) receptors designed to promote sleep onset and maintenance at doses that show minimal or no residual next-day somnolence (drowsiness) or psychomotor i...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 28, 2020